Critical shortage in BCG immunotherapy: How did we get here and where will it take us?-Reference-Cited by-同舟云学术

Critical shortage in BCG immunotherapy: How did we get here and where will it take us?

Published:2022-01 Issue:1 Volume:40 Page:1-3
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Harvey Michael^ORCID,Chislett Bodie,Perera Marlon,Lawrentschuk Nathan,Bolton Damien^ORCID,Jack Gregory

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference21 articles.

1. Die Aetiologie der Tuberculose;Koch;Berliner Klinische Wochenschrift,1882

2. Calmette A. L'infection bacillaire et la tuberculose chez l'homme et chez les animaux: processus d'infection, et de defense, étude biologique et expérimentale. 1922.

3. Cancer and tuberculosis;Pearl;Am J Hygeine,1929

4. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse;Old;Nature,1959

5. An endotoxin-induced serum factor that causes necrosis of tumors;Carswell;Proc Natl Acad Sci U S A,1975

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Impact of Bladder Cancer in the USA;PharmacoEconomics - Open;2024-08-18

2. Editorial Commentary;Urology Practice;2024-07

3. Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer;Life;2024-06-22

4. Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment;Frontiers in Oncology;2024-03-08

5. Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability;Journal of Chemotherapy;2024-03-04